A review of interim findings from the AMBASSADOR study looking at adjuvant pembrolizumab in patients with muscle-invasive urothelial carcinoma.
ENVISION Trial of UGN-102 Shows Durable Responses in LG-IR-NMIBC
February 3rd 2025Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment for patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer.
Read More